Skip to content
Disclosery

Commodore Capital LP

Follow

13F filer, CIK 1831942, NEW YORK, NY

Commodore Capital LP reported $1,728,452,370 across 36 holdings for the quarter ended 2026-03-31, in a 13F-HR filed 2026-05-15. Its ten largest share positions make up 61.35% of the portfolio.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001831942-26-000025

Period
2026-03-31
Reported value
$1.73B
Holdings
36
Top 10 weight
61.35%
New
13
Sold out
10

Part of the filer group Commodore Capital LP

  • Commodore Capital Master LP
  • Michael Kramarz
  • Robert Egen Atkinson
How groups are built

Stakes and trades reported after 2026-03-31

13D, 13G and Form 4 filings by this filer's group, dated after the 13F period, on securities the quarter does not hold as shares.

  • SGMT SAGIMET BIOSCIENCES INC: 13G 5,507,752 shares, 7.6% of the class, 13G filed 2026-10-07, 0001831942-26-000045Timeline
    Accepted , ingested
  • SRZN SURROZEN INC: 13G 885,000 shares, 7.5% of the class, 13G filed 2026-10-01, 0001831942-26-000044Timeline
    Accepted , ingested

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ERASnew+3,175,000$51.4M
DMRAnew+1,939,000$50.2M
DFTXnew+2,000,000$37.8M
EYPTnew+2,825,000$36.4M
CRVSnew+2,258,735$33M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
TERNexited-1,475,000-$59.6M
XENEreduced-975,000-$56.7M
ELVNreduced-1,417,809-$55.6M
ORKAexited-1,753,054-$53.1M
PTGXexited-450,000-$39.3M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q1 2026

Share positions as resolved from 13F-HR 0001831942-26-000025, largest first. % of portfolio is the value over $1,728,452,370, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 13,350,000 shares; 2025Q3: 17,000,000 shares; 2025Q4: 17,000,000 shares; 2026Q1: 17,000,000 shares 17,000,000$169M9.79%0Timeline
ALKSALKERMES PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,900,000 shares; 2024Q4: 2,300,000 shares; 2025Q1: 1,950,000 shares; 2025Q2: 2,450,000 shares; 2025Q3: 3,096,754 shares; 2025Q4: 3,550,000 shares; 2026Q1: 4,200,000 shares 4,200,000$149M8.59%+650,000Timeline
ELVNENLIVEN THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 4,100,000 shares; 2024Q4: 4,205,000 shares; 2025Q1: 4,675,000 shares; 2025Q2: 4,692,809 shares; 2025Q3: 4,692,809 shares; 2025Q4: 4,692,809 shares; 2026Q1: 3,275,000 shares 3,275,000$128M7.43%-1,417,809Timeline
COGTCOGENT BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 7,539,930 shares; 2024Q4: 6,881,629 shares; 2025Q1: 8,892,816 shares; 2025Q2: 2,311,164 shares; 2025Q3: 7,250,000 shares; 2025Q4: 2,196,845 shares; 2026Q1: 2,888,007 shares 2,888,007$111M6.43%+691,162Timeline
SYRESPYRE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,988,084 shares; 2024Q4: 1,988,084 shares; 2025Q1: 1,988,084 shares; 2025Q2: 1,988,084 shares; 2025Q3: 1,988,084 shares; 2025Q4: 2,388,245 shares; 2026Q1: 1,912,380 shares 1,912,380$96.5M5.58%-475,865Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 950,000 shares; 2025Q2: 3,100,000 shares; 2025Q3: 3,375,000 shares; 2025Q4: 3,375,000 shares; 2026Q1: 2,475,000 shares 2,475,000$94.8M5.48%-900,000Timeline
CLDXCELLDEX THERAPEUTICS INC NEWQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,618,937 shares; 2024Q4: not reported; 2025Q1: 3,200,000 shares; 2025Q2: 3,450,000 shares; 2025Q3: 3,028,335 shares; 2025Q4: 2,565,000 shares; 2026Q1: 2,696,616 shares 2,696,616$85.5M4.95%+131,616Timeline
NUVLNUVALENT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 940,000 shares; 2024Q4: 1,621,600 shares; 2025Q1: 1,855,000 shares; 2025Q2: 1,375,000 shares; 2025Q3: 1,400,000 shares; 2025Q4: 550,000 shares; 2026Q1: 833,600 shares 833,600$85.4M4.94%+283,600Timeline
AMLXAMYLYX PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,075,478 shares; 2025Q4: 5,650,000 shares; 2026Q1: 5,650,000 shares 5,650,000$78.5M4.54%0Timeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: 750,000 shares; 2025Q3: 750,000 shares; 2025Q4: 750,000 shares; 2026Q1: 750,000 shares 750,000$62.5M3.61%0Timeline
ANROALTO NEUROSCIENCE INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 1,823,196 shares; 2026Q1: 2,723,196 shares 2,723,196$61.2M3.54%+900,000Timeline
PHVSPHARVARIS N VQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,911,433 shares; 2024Q4: 1,911,433 shares; 2025Q1: 1,911,433 shares; 2025Q2: 1,911,433 shares; 2025Q3: 2,418,476 shares; 2025Q4: 1,889,445 shares; 2026Q1: 1,918,970 shares 1,918,970$54.2M3.14%+29,525Timeline
ERASERASCA INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,175,000 shares 3,175,000$51.4M2.97%newTimeline
DMRADAMORA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,939,000 shares 1,939,000$50.2M2.91%newTimeline
XENEXENON PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 2,700,000 shares; 2024Q4: 2,740,000 shares; 2025Q1: 2,325,000 shares; 2025Q2: 3,025,000 shares; 2025Q3: 2,700,000 shares; 2025Q4: 1,800,000 shares; 2026Q1: 825,000 shares 825,000$48M2.78%-975,000Timeline
DFTXDEFINIUM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,000,000 shares 2,000,000$37.8M2.19%newTimeline
LBRXLB PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,500,000 shares; 2025Q4: 1,500,000 shares; 2026Q1: 1,500,000 shares 1,500,000$37M2.14%0Timeline
EYPTEYEPOINT INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,825,000 shares 2,825,000$36.4M2.11%newTimeline
NRIXNURIX THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,650,000 shares; 2024Q4: 3,000,000 shares; 2025Q1: 3,978,907 shares; 2025Q2: 3,948,653 shares; 2025Q3: 3,780,055 shares; 2025Q4: 2,275,000 shares; 2026Q1: 2,275,000 shares 2,275,000$35.3M2.04%0Timeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,258,735 shares 2,258,735$33M1.91%newTimeline
ASMBASSEMBLY BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 1,000,000 shares; 2025Q4: 1,000,000 shares; 2026Q1: 1,000,000 shares 1,000,000$27.8M1.61%0Timeline
CATXPERSPECTIVE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 3,350,000 shares; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 6,336,782 shares 6,336,782$26.4M1.53%newTimeline
SLNOSOLENO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 1,260,000 shares; 2024Q4: 1,525,000 shares; 2025Q1: 1,150,000 shares; 2025Q2: 610,000 shares; 2025Q3: 1,350,000 shares; 2025Q4: 1,200,000 shares; 2026Q1: 652,432 shares 652,432$21.8M1.26%-547,568Timeline
OCULOCULAR THERAPEUTIX INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,575,000 shares 2,575,000$21.8M1.26%newTimeline
IPSCCENTURY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 8,695,652 shares 8,695,652$19.7M1.14%newTimeline
ZURAZURA BIO LTDQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 3,250,000 shares 3,250,000$19.3M1.12%newTimeline
SABSSAB BIOTHERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 4,401,500 shares; 2025Q4: 4,401,500 shares; 2026Q1: 4,401,500 shares 4,401,500$16.9M0.98%0Timeline
PALIPALISADE BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 11,445,000 shares; 2026Q1: 7,181,062 shares 7,181,062$12.6M0.73%-4,263,938Timeline
KPTIKARYOPHARM THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 1,950,000 shares 1,950,000$10.9M0.63%newTimeline
IKTINHIBIKASE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: 5,925,000 shares; 2025Q1: 5,344,432 shares; 2025Q2: 5,397,488 shares; 2025Q3: 5,397,488 shares; 2025Q4: 5,397,488 shares; 2026Q1: 5,397,488 shares 5,397,488$9.07M0.52%0Timeline
ANTXAN2 THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 2,333,713 shares 2,333,713$7.98M0.46%newTimeline
PEPGPEPGEN INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: 2,357,319 shares; 2025Q4: 3,400,000 shares; 2026Q1: 4,475,000 shares 4,475,000$7.92M0.46%+1,075,000Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: 483,000 shares; 2024Q4: 483,000 shares; 2025Q1: 483,000 shares; 2025Q2: 483,000 shares; 2025Q3: 483,000 shares; 2025Q4: 483,000 shares; 2026Q1: 483,000 shares 483,000$7.21M0.42%0Timeline
HLXCHELIX ACQUISITION CORP IIIQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 500,000 shares 500,000$5.08M0.29%newTimeline
LONALEONABIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 464,398 shares; 2026Q1: 464,398 shares 464,398$4.77M0.28%0Timeline
RLMDRELMADA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 633,901 shares 633,901$4.41M0.26%newTimeline

Sold out in Q1 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
TERNTERNS PHARMACEUTICALS INC1,475,000$59.6Mshares
ORKAORUKA THERAPEUTICS INC1,753,054$53.1Mshares
PTGXPROTAGONIST THERAPEUTICS INC450,000$39.3Mshares
CTMXCYTOMX THERAPEUTICS INC.7,692,300$32.8Mshares
MIND MEDICINE MINDMED INCMIND MEDICINE MINDMED INC2,000,000$26.8Mshares
CNTACENTESSA PHARMACEUTICALS PLC1,000,000$25Mshares
REPLREPLIMUNE GROUP INC1,425,000$13.9Mshares
CTNMCONTINEUM THERAPEUTICS INC816,326$9.33Mshares
RAPTRAPT THERAPEUTICS INC250,000$8.47Mshares
DRUGBRIGHT MINDS BIOSCIENCES INC18,851$1.47Mshares

How Q1 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001831942-26-000025 base2026-05-15acceptance time not in the bulk data set